Jacobs Levy Equity Management
CRMD icon

Jacobs Levy Equity Management’s CorMedix CRMD Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,674
Closed -$74K – 1041
2020
Q2 		$74K Buy
+11,674
New +$54K ﹤0.01% 1017

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Elliott Investment Management
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Cresset Asset Management
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management's CRMD Position: Q3 2020 in Review

Jacobs Levy Equity Management sold out of CorMedix (CRMD) in Q3 2020, closing a stake of 11,674 shares — an estimated $74K sold.

Jacobs Levy Equity Management first reported a position in CRMD in Q2 2020 and held it in 1 quarter. The position peaked at $74K in Q2 2020. 71 funds tracked by Wall St. Rank hold CRMD as of Q3 2020.

  • Jacobs Levy Equity Management reported no remaining CorMedix position as of Q3 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 11,674 CorMedix shares in Q3 2020, an estimated $74K.
  • Jacobs Levy Equity Management first reported a position in CorMedix in Q2 2020 and held it in 1 quarter.
  • Jacobs Levy Equity Management's CorMedix position peaked at $74K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held CorMedix as of Q3 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.